Cancer Research Institute, New York City
23
2
2
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
17.4%
4 terminated/withdrawn out of 23 trials
80.0%
-6.5% vs industry average
0%
0 trials in Phase 3/4
94%
15 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (23)
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Role: collaborator
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
Role: collaborator
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Role: collaborator
Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Role: collaborator
Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors
Role: collaborator
Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations
Role: collaborator
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )
Role: collaborator
Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
Role: collaborator
Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer
Role: collaborator
Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma
Role: collaborator
Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Role: collaborator
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
Role: collaborator
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Role: collaborator
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
Role: collaborator
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
Role: collaborator
Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
Role: collaborator
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
Role: collaborator
Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer
Role: collaborator
Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC
Role: collaborator
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
Role: collaborator